Tag
#HROW
-
2026
-
HROW – 8-K
-
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
-
HROW – 8-K
-
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
-
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
-
HROW – 8-K
-
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
-
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
-
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
-
HROW – 8-K
-
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
-
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
-
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
-
HROW – 10-K
-
HROW – 8-K
-
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
-
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
-
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
-
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
-
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
-
HROW – 8-K
-
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth